EGFR and non-small cell lung carcinoma: Next-generation-sequencing (NGS) of early-stage NSCLC for genetic alterations following surgical resection is not currently done in many Canadian provinces or institutions internationally, despite the demonstrated survival benefit with Osimertinib for common sensitizing tyrosine kinase inhibitors to EGFR [8].